Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Deals PIC

CellStore Signs Strategic Partnership Memorandum With Shanghai Cell Therapy Group – Deepening Cooperation in Cell Cryopreservation, Product Application Validation, and Industrial Synergy Across Cell and Gene Therapy

Fineline Cube Sep 10, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Deals

Canhelp Genomics Partners with Mirxes to Expand Tumor Origin Testing in Southeast Asia

Fineline Cube Nov 13, 2024

Canhelp Genomics, a Chinese company specializing in oncology-focused molecular diagnostics, has formed a strategic partnership...

Company Deals

Vesalius Therapeutics Partners with GSK for Novel Parkinson’s Disease Treatments

Fineline Cube Nov 13, 2024

US-based Vesalius Therapeutics has entered into a strategic agreement with UK pharmaceutical giant GSK plc...

Company Deals

Flare Therapeutics and Roche Enter Strategic Collaboration for Oncology Drug Discovery

Fineline Cube Nov 13, 2024

US-based Flare Therapeutics Inc., a clinical-stage biotech company specializing in cancer therapies through the use...

Company Deals

Schrödinger and Novartis Ink Deal to Accelerate Drug Discovery Candidates

Fineline Cube Nov 13, 2024

New York-based Schrödinger, Inc. (NASDAQ: SDGR), a leading software provider in accelerating drug discovery, has...

Company Drug

CSPC Pharmaceutical Gains NMPA Approval for Clinical Trial of mRNA Vaccine SYS6026

Fineline Cube Nov 13, 2024

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received clinical trial...

Policy / Regulatory

NHSA and MoF Announce Medical Insurance Fund Prepayment Initiative to Aid Healthcare Institutions

Fineline Cube Nov 12, 2024

The National Healthcare Security Administration (NHSA) and the Ministry of Finance (MoF) have jointly issued...

Company

InnoCare Pharma Reports 29.8% Revenue Increase in Q3 2024 Financials

Fineline Cube Nov 12, 2024

Beijing-based biotech InnoCare Pharma (HKG: 9969; SHA: 688428) has released its financial report for the...

Company Deals

Triton Partners Mulls Acquisition of Germany’s Evotec SE, Shares Soar 22%

Fineline Cube Nov 12, 2024

Private equity firm Triton Partners is reportedly contemplating the acquisition of Germany-based Evotec SE (NASDAQ:...

Company

GenScript Biotech Expands in Australia with New Sydney Operations and Logistics Center

Fineline Cube Nov 12, 2024

GenScript Biotech Corporation (HKG: 1548), a leading Chinese biotechnology company, has announced the establishment of...

Company Deals

Leman Biotech Secures Over USD 13.9 Million in Series A Financing for Next-Gen Cancer Immunotherapies

Fineline Cube Nov 12, 2024

China-based Leman Biotech Co., Ltd. has reportedly completed the first closing of its Series A...

Company Deals

Biocytogen’s First-in-Class B7H3/PTK7 Bispecific ADC Option Exercised by IDEAYA Biosciences

Fineline Cube Nov 12, 2024

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced that its...

Company Drug

Gan & Lee’s GZR18 Shows Significant Weight Loss in Phase IIb Study at ObesityWeek 2024

Fineline Cube Nov 12, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced the oral presentation...

Company Drug

J&J’s Nipocalimab Receives FDA Breakthrough Therapy Designation for Sjögren’s Disease

Fineline Cube Nov 12, 2024

US-based pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has announced that it has received...

Company Drug

Zai Lab and argenx Receive NMPA Approval for Vygart Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

Fineline Cube Nov 12, 2024

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) and its US partner argenx SE...

Company Drug

Cutia Therapeutics’ CU-10201 Receives NMPA Approval for Acne Vulgaris Treatment

Fineline Cube Nov 12, 2024

Cutia Therapeutics (HKG: 2487), a developer of dermatology therapies, has announced that its CU-10201, a...

Company Drug

BeyondSpring Presents Positive Phase II Data for Plinabulin Combination Therapy in NSCLC at SITC

Fineline Cube Nov 12, 2024

BeyondSpring Inc. (NASDAQ: BYSI), a US-based biotech company, has announced the presentation of the latest...

Company Drug

Abbisko Therapeutics’ Pimicotinib Meets Primary Endpoint in Phase III MANEUVER Study for TGCT

Fineline Cube Nov 12, 2024

hanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has revealed positive top-line results from the...

Company Drug

ETERN Therapeutics’ ETS-006 Receives FDA Orphan Drug Designation for Pleural Mesothelioma

Fineline Cube Nov 12, 2024

ETERN Therapeutics, a Shanghai-based developer of small-molecule anti-tumor drugs, has announced that it has received...

Company Drug

Frontera Therapeutics Receives FDA Approval for Phase II Study of FT-003 in nAMD

Fineline Cube Nov 12, 2024

Frontera Therapeutics, Inc., a Sino-US biopharmaceutical company, has announced that it has received approval from...

Company

Viatris Reports Q3 2024 Global Sales of USD 3.8 Billion with a 5% YOY Decline

Fineline Cube Nov 11, 2024

US generics giant Viatris (NASDAQ: VTRS) has published its financial report for the third quarter...

Posts pagination

1 … 321 322 323 … 718

Recent updates

  • Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers
  • METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform
  • Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection
  • CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours
  • HBM Partner Solstice Oncology Launches with US$225 Million Series A Led by RA Capital – Advancing Second‑Generation CTLA‑4 Antibody Porustobart in Neoadjuvant Oncology
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Company Drug

CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.